Form 4 for CRL Charles River Laboratories
Accepted 2026-02-03 00:00:00 ET · period of report 2026-01-30 · accession 0001100682-26-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-03 | 2026-01-30 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | A - Grant | $0.00 | +5,456 | 29.2K | +23% | $0 | |
| 2026-02-03 | 2026-01-30 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | F - Tax | $211.68 | -1,749 | 27.4K | -6% | -$370.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-30 | A | A | 5,456 | $0.00 | 29,172 | D | — | — | (F1) Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023. |
| 2 | Common | Common Stock | 2026-01-30 | F | D | 1,749 | $211.68 | 27,423 | D | — | — |